MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Cognitive dysfunction"

  • 2022 International Congress

    Common mistakes in the MoCA test in patients with Parkinson’s Disease in Kyrgyzstan

    A. Il'Yazova, C. Shambetova, E. Zhunusova (Bishkek, Kyrgyzstan)

    Objective: The aim of the study is to identify common mistakes in MoCA in patients with Parkinson’s disease (PD) in Kyrgyzstan. Background: Cognitive impairment is…
  • 2022 International Congress

    The East London Parkinson Disease Project – engaging a diverse population in research

    A. Zirra, A. Ben-Joseph, T. Haque, D. Gallagher, C. Budu, B. Huxford, C. Simonet, A. Noyce (London, United Kingdom)

    Objective: The objective of this study was to engage a diverse group of people with Parkinson disease (PwP) from East London and build a research…
  • 2022 International Congress

    Priorities of PD patients for treatment of cognitive-driven ADL impairment

    I. Liepelt-Scarfone, M. Bentele, S. Becker, C. Altmann, E. Schaeffer, K. Michaelis, S. Solbrig, K. Brockmann (Tübingen, Germany)

    Objective: To define cognitive-driven impairments in activities of daily living (ADL) with high priority for rehabilitation ranked by Parkinson’s disease (PD) patients. Background: Impairments in…
  • 2022 International Congress

    History of Comorbidities and their Association with Developing Cognitive Dysfunction in PD

    C. Venuto, K. Kieburtz, K. Herbst, G. Smith (Rochester, USA)

    Objective: To examine comorbidities associated with incident cognitive dysfunction in PD. Background: The risk of dementia is up to six-times higher in PD compared to…
  • 2022 International Congress

    MRI to investigate cerebrovascular changes in Parkinson’s disease

    D. Nolan, D. Myall, C. Morgan, R. Shoorangiz, L. Livingston, S. Grenfell, T. Pitcher, M. Macaskill, K-L. Horne, C. Le Heron, S. Marsh, J. Dalrymple-Alford, T. Anderson, T. Melzr (Christchurch, New Zealand)

    Objective: To determine the value of MRI-derived cerebrovascular metrics and their relationship with global cognitive impairment in Parkinson’s disease (PD). Background: Cognitive impairment is a…
  • 2022 International Congress

    A second level neuropsychological battery for Parkinson’s Disease. Normative data from the Italian population.

    T. Gandolfi, G. Arcara, S. Cuoco, C. Siri, L. Weis, E. Reali, M. Garon, F. Pistonesi, V. Cianci, E. Fiorenzato, G. Santangelo, G. Pezzoli, P. Barone, A. Antonini, R. Biundo (Padova, Italy)

    Objective: The main purpose of this work is to propose modern Italian co-normed data for a battery of ten widely used neuropsychological tests for Parkinsons’…
  • 2022 International Congress

    Cognition in parkinson disease: Tunisian clinical experience

    F. Syrine, B. Nadia, H. Hela, F. Saloua, B. Mariem, FRE. Mohamed (tunis, Tunisia)

    Objective: In this study, we identified among Parkinson Disease patients those pre-disposed to cognitive impairment, and described their clinical profiles. Background: Parkinson disease (PD) is…
  • 2022 International Congress

    Impact of ApoE genotype on cognition in idiopathic and genetic forms of Parkinson’s disease

    C. Koros, K. Brockmann, Aμ. Simitsi, A. Bougea, H. Liu, ακ. Hauser, C. Schulte, I. Pachi, N. Papagiannakis, A. Zahou, I. Wurster, E. Efthymiopoulou, I. Beratis, R. Antonelou, M. Maniati, M. Moraitou, H. Michelakakis, G. Paraskevas, S. Papageorgiou, C. Potagas, D. Papadimitriou, M. Bozi, M. Stamelou, T. Gasser, L. Stefanis (Athens, Greece)

    Objective: The aim of our current report was to assess the impact of Apolipoprotein-E (ApoE) genotype on cognition in idiopathic Parkinson’s disease (PD) patients and…
  • 2022 International Congress

    MoCA and MMSE subitems’ sensitivity across the PD-cognitive spectrum

    E. Fiorenzato, L. Zurlo, C. Cianci, M. Garon, T. Gandolfi, F. Pistonesi, L. Weis, A. Antonini, R. Biundo (Padua, Italy)

    Objective: To determine which Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) subitems are more sensitive in detecting cognitive abnormalities in patients with PD…
  • 2022 International Congress

    SelfCog®: a digitized cognitive battery to classify Parkinson disease (PD) patients with or without Mild Cognitive Impairment (MCI)

    J. Montillot, R. Massart, K. Hernandez, M. Lunven, G. Fénelon, H. Salhi, A. Bachoud-Lévi, P. Rémy (Créteil, France)

    Objective: We tested the performance of the SelfCog® to classify PD patients as MCI. Background: MCI is a strong risk factor of dementia in PD…
  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 117
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley